Clinical Trial Update: Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tofacitinib as a glucocorticoid-sparing agent in polymyalgia rheumatica has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Polymyalgia Rheumatica, Effect of Drug | Phase 2 | Status: COMPLETED